BIOVIC - Novel breast cancer test is reporting tomorrow
-
Biovica Int (BIOVIC), Sweden based novel breast cancer test company is reporting tomorrow.
BIOVIC is down 50% due to delay of FDA approval due to FDA covid congestion. The thesis is unchanged. FDA covid related delay should not change the valuation.
Biovica – our doubling candidate is reporting tomorrow
I have been long Biovica (BIOVIC) for some time. The thesis has been delayed by the FDA approval delay due to FDA Covid congestion. Many retail investors lost patience. The stock is down, but the thesis is unchanged. One or two months delay should not affect the value of the company. FDA Covid-caused FDA congestion…
Fit Investment Ideas (fitinvestmentideas.com)
-
God tekst at læse når man har en pæn stak, ikke mindst linjen under overskriften. Nå, seriøst er det en af de mere sikre bioteks. Belønningen er nu ikke længere ude i kimningen, men lige ude over rælingen:-)
-
Biovica FDA udmelding udsat til ultimo 21 grundet travlhed.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind